Novartis
NVS
$114.52
Share price
-3.25%
Change (1 day)
3.61%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Novartis (NVS) Fails to deliver data
Key failure to deliver metrics for Novartis:
- Last SEC data release: 2025-06-30
- Last 15 days FTD volume: $0.39 M
- Last 3 months FTD volume: $8.82 M
- Last year FTD volume: $8.82 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Novartis (NVS) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Novartis (NVS) - since 2013
Volume in USD (price x number of shares), data since 2013Novartis (NVS) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | $53.8 M | -62.76% |
| 2024 | $0.14 B | 88.96% |
| 2023 | $76.46 M | -33.95% |
| 2022 | $0.11 B | 13.59% |
| 2021 | $0.10 B | -28.35% |
| 2020 | $0.14 B | -21.65% |
| 2019 | $0.18 B | 18.03% |
| 2018 | $0.15 B | 48.59% |
| 2017 | $0.10 B | -62.29% |
| 2016 | $0.27 B | -38.77% |
| 2015 | $0.44 B | 149.55% |
| 2014 | $0.17 B | 59.41% |
| 2013 | $0.11 B |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Merck MRK | $12.12 M | $0.17 B | 🇺🇸 USA |
 Pfizer PFE | $26.37 M | $0.27 B | 🇺🇸 USA |
 Johnson & Johnson JNJ | $10.58 M | $0.12 B | 🇺🇸 USA |
 Sanofi SNY | $46.75 M | $67.7 M | 🇫🇷 France |
 GlaxoSmithKline GSK | $0.11 B | $0.38 B | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $8.83 M | $41.28 M | 🇮🇱 Israel |
 Bristol-Myers Squibb BMY | $11.54 M | $0.26 B | 🇺🇸 USA |
 Abbott Laboratories ABT | $36.35 M | $0.37 B | 🇺🇸 USA |
 AstraZeneca AZN | $23.77 M | $0.14 B | 🇬🇧 UK |